
Ellads
Novartis (NVS) Tuesday said that the US FDA has approved Cosentyx (secukinumab) 150 mg for adults with polymyalgia rheumatica who do not respond adequately to corticosteroids or cannot tolerate dose reductions, making it the first and only anti-IL-17 biologic approved for the